Martha Sklavos, PhD, PMP provides drug development expertise for the novel technologies being developed at Mass General Brigham, with a focus on the gene & cell therapy portfolio and Brigham Ignite programs. Martha has gained broad development expertise as a result of managing multiple complex projects and portfolios composed of various drug modalities including small molecules, monoclonal and bispecific antibodies, antibody-drug conjugates, peptide conjugates and cell therapies across the stages of drug development. At MedImmune she led management of the antibody drug conjugate (ADC) portfolio including assets spanning discovery research through Phase 1/2. When she joined Oncology Medical Affairs at AstraZeneca she led the strategic management of the successful launch of Calquence in first line (1L) chronic lymphocytic leukemia (CLL). As the Head of Pipeline Operations at Arcellx, she established the Operations function and ensured delivery of 3 INDs and 1 Pivotal Phase 2 ready asset.
Prior to joining industry, Martha earned her undergraduate degree from Johns Hopkins University, her PhD in Immunology from the University of Pittsburgh School of Medicine and completed her post-doctoral research at the National Cancer Institute/Frederick National Laboratory for Cancer Research. Martha is also the Founder and CEO of Aloe Therapeutics, a biotech start-up developing cell-based immunotherapies for advanced solid tumors.